PTC Therapeutics Reports Third Quarter 2015 Financial Results, Provides Corporate Update and Reviews Key Findings from ACT DMD

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. META
6. TSLA
7. SMCI
8. RTX
9. S
10. COF

Go back to PTC Therapeutics Reports Third Quarter 2015 Financial Results, Provides Corporate Update and Reviews Key Findings from ACT DMD

PTC Therapeutics (PTCT) Bullish Stance Reiterated at Cowen on Strong Translarna Sales Growth

November 10, 2015 9:34 AM EST

PTC Therapeutics (NASDAQ: PTCT) reported 3Q15 EPS of $(1.27), vs consensus $(1.14). Translarna revenues were $9.8MM, a 59% QoQ growth in sales, vs consensus of $10.4MM.

Investor focus is on if FDA accepts Translarna's rolling NDA (which we think is very likely, target completion... More

PTC Therapeutics (PTCT) Misses Q3 EPS by 12c

November 9, 2015 4:49 PM EST

PTC Therapeutics (NASDAQ: PTCT) reported Q3 EPS of ($1.27), $0.12 worse than the analyst estimate of ($1.15). Revenue for the quarter came in at $9.78 million versus the consensus estimate of $9.88 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.

... More